Regulatory News In Brief
This article was originally published in The Tan Sheet
Executive Summary
Proposals to change supplement regs tabled in Senate; Senate wants firm sunscreen rule compliance date; 2012 sees rise in tainted sexual enhancement supplements.
You may also be interested in...
In Brief
FDA softens disclaimer for green tea QHC; Formulife/Purus covers spectrum of violations; NAD refers Schick case to FTC; Genomma drops Prestige Brands board bid.
Conflict Of Interest Rules Removed In Draft Of House User Fee Bill
Reforms would end waiver caps for conflicts of interest, but whether they will solve the problems patient groups and others have with the advisory committee selection process is unclear. In a discussion draft, FDA could issue as many waivers of financial conflicts as it chose.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.